ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Impact of lisinopril on cisplatin-induced inflammation, oxidative stress, apoptosis, and impaired steroidogenesis in rat testis: involvement of Nrf2/Keap1/HO-1 and PPARγ signaling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Testicular dysfunction is a significant long-term side effect of the chemotherapeutic drug cisplatin (CDDP), primarily due to DNA damage and oxidative stress. Lisinopril (LSP), an angiotensin-converting enzyme (ACE) inhibitor commonly used for hypertension treatment, has a debated impact on reproductive function. This study investigates, for the first time, the ability of LSP to counteract CDDP-induced inflammation, oxidative stress, apoptosis, and steroidogenic disturbances in rat testis. In addition, LSP's effect on testicular Nrf2/Keap1/HO-1 and PPARγ signaling is examined. Rats were divided into Control, LSP, CDDP, and LSP + CDDP groups. Rats were treated with 10 mg/kg of LSP orally for 10 days, and blood and testis samples were collected after sacrifice for histopathological, biochemical, and genetic analysis. Our results revealed that LSP administration with CDDP effectively increased luteinizing, follicle-stimulating, and testosterone hormone levels (effect size f = 2.56, 2.32, and 3.02; respectively, and power = 1.00) and upregulated testicular expression of CYP11a1, HSD17B3, and StAR genes. LSP counteracted the histopathological aberrations induced by CDDP. The LSP + CDDP group also showed increased levels of reduced glutathione and superoxide dismutase (effect size f = 1.72 and power = 0.99) and decreased levels of malondialdehyde (effect size f = 3.07 and power = 1), interleukin-1β, tumor necrosis factor-α, interleukin-6, nuclear factor kappa B, cyclooxygenase-2, and cleaved caspase 3 (effect size f = 4.61 and power = 1). On the molecular level, the LSP + CDDP group showed a reduction in Keap1 protein level but an increase in Nrf2 (effect size f = 5.50 and power = 1), HO-1 (effect size f = 3.66 and power = 1), and PPARγ protein levels, compared to the CDDP group. In conclusion, LSP revealed prominent anti-oxidant, anti-apoptotic, and anti-inflammatory effects protecting against CDDP-induced testicular damage. Moreover, it preserved the steroidogenic process and testicular tissue characteristics. LSP modulated the expression of Nrf2/Keap1/HO-1 and PPARγ signaling. Therefore, our data presents LSP as a promising candidate for enhancing reproductive health in patients undergoing CDDP treatment.
Indexed as
Identifiers
40009171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.